rheumatoid

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.[1]

Paridiprubart (NI-0101), a humanized monoclonal antibody targeting TLR4, offers promising research avenues for rheumatoid arthritis [1].

Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling. GM-CSF may contribute to an overactive inflammatory response linked to respiratory failure and death and could be used to study rheumatoid arthritis.

Golimumab (CNTO-148) is a potent humanized anti-TNFα IgG1κ monoclonal antibody with anti-inflammatory and anticancer activity. It inhibits the production of IL-6 and IL-1β, induces apoptosis, and can be used to prevent inflammation and destruction of cartilage or bone. This makes Golimumab valuable for studying rheumatoid arthritis and cancer.

Sarilumab (SAR-153191)is a potent interleukin-6 IL-6 receptor antagonist and a human immunoglobulin G1 monoclonal antibody. Sarilumab inhibits IL-6-mediated signaling and reduces inflammation.Sarilumab is used for the prevention and treatment of rheumatoid arthritis.

Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10. It has anti-inflammatory properties, selectively binds to CXCL10, and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Fletikumab (NNC0109-0012) is a monoclonal antibody that inhibits IL-20, primarily used in research on rheumatoid arthritis and psoriasis.

Olokizumab (CDP-6038) is a humanized anti-IL-6 monoclonal antibody that selectively blocks the final assembly of the IL-6 signaling complex for the study of rheumatoid arthritis (RA).

Tabalumab (LY2127399), a humanized monoclonal antibody (IgG4 type) targeting B-cell activating factor (BAFF), exhibits neutralizing activity against both membrane-bound and soluble BAFF. This compound is relevant for research into autoimmune diseases, including rheumatoid arthritis, renal failure, and systemic lupus erythematosus [1].

Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production. Itolizumab can be used to study conditions such as psoriasis, rheumatoid arthritis (RA), and COVID-19 disease.

Cabiralizumab (FPA 008), an anti-CSF1R monoclonal antibody (MAb), promotes T cell infiltration and boosts antitumor immune responses. It also prevents osteoclast activation, thereby inhibiting bone destruction, and is utilized in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab can be paired with Nivolumab in lung cancer studies [1] [2].

Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF (granulocyte-macrophage colony-stimulating factor) by binding to its ligand with high affinity, and is used in the study of rheumatoid arthritis and active axial spondyloarthritis.

Sirukumab (CNTO-136) is a selective humanized monoclonal antibody binding to Interleukin-6 (IL-6), inhibiting IL-6-mediated signal transduction and activation of transcription factors. It is used in lupus nephritis and rheumatoid arthritis research.

Vobarilizumab (ALX-0061) is a humanized, specific monoclonal antibody targeting IL-6R and albumin (ALB), consisting of an anti-IL-6R domain and an anti-human albumin domain, used in the study of rheumatoid arthritis and other autoimmune diseases.

Quetmolimab is a humanized monoclonal antibody targeting chemokine ligand 1 (CX3CL1) that can be used to study rheumatoid arthritis.

Adalimumab beta (ABP-501) is an anti-TNF-α monoclonal antibody used in rheumatoid arthritis (RA) research [1].

Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.